<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Cardiovasc Diabetol</journal-id><journal-title>Cardiovascular Diabetology</journal-title><issn pub-type="epub">1475-2840</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1475-2840-8-31</article-id><article-id pub-id-type="pmid">19527523</article-id><article-id pub-id-type="doi">10.1186/1475-2840-8-31</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>The common G-866A polymorphism of the <italic>UCP2 </italic>gene and survival in diabetic patients following myocardial infarction</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Palmer</surname><given-names>Barry R</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>barry.palmer@otago.ac.nz</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Devereaux</surname><given-names>Courtney L</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I4">4</xref><email>courtney.devereaux@du.edu</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Dhamrait</surname><given-names>Sukhbir S</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>sukhbirdhamrait@hotmail.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Mocatta</surname><given-names>Tessa J</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>tessa.mocatta@otago.ac.nz</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Pilbrow</surname><given-names>Anna P</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>anna.pilbrow@otago.ac.nz</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Frampton</surname><given-names>Chris M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>statistecol@xtra.co.nz</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Skelton</surname><given-names>Lorraine</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lorraine.skelton@cdhb.govt.nz</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Yandle</surname><given-names>Tim G</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>tim.yandle@cdhb.govt.nz</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Winterbourn</surname><given-names>Christine C</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>christine.winterbourn@otago.ac.nz</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Richards</surname><given-names>A Mark</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mark.richards@cdhb.govt.nz</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Montgomery</surname><given-names>Hugh E</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>rmhahum@ucl.ac.uk</email></contrib><contrib id="A12" contrib-type="author"><name><surname>Cameron</surname><given-names>Vicky A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>vicky.cameron@otago.ac.nz</email></contrib></contrib-group><aff id="I1"><label>1</label>Christchurch Cardioendocrine Research Group, Department of Medicine, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand</aff><aff id="I2"><label>2</label>Centre for Cardiovascular Genetics, British Heart Foundation Laboratories, Royal Free and University College London Medical School, London WC1E 6JF, UK</aff><aff id="I3"><label>3</label>Free Radical Research Group, Department of Pathology, University of Otago, Christchurch, PO Box 4345, Christchurch, New Zealand</aff><aff id="I4"><label>4</label>Current address : University of Denver, 2199 S. University Blvd., Denver, Colorado 80208, USA</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>15</day><month>6</month><year>2009</year></pub-date><volume>8</volume><fpage>31</fpage><lpage>31</lpage><ext-link ext-link-type="uri" xlink:href="http://www.cardiab.com/content/8/1/31"/><history><date date-type="received"><day>3</day><month>4</month><year>2009</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Palmer et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Palmer et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Palmer R Barry barry.palmer@otago.ac.nz </dc:author><dc:title> The common G-866A polymorphism of the UCP2 gene and survival in diabetic patients following myocardial infarction </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Cardiovascular Diabetology 8(1): 31-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1475-2840(2009)8:1&#x0003c;31&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1475-2840</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>A variant in the promoter of the human uncoupling protein 2 (UCP2) gene, the G-866A polymorphism, has been associated with future risk of coronary heart disease events, in those devoid of traditional risk factors and in those suffering from diabetes. We thus examined the impact of the G-866A polymorphism on 5-year survival in a cohort of 901 post-myocardial infarction patients, and the impact of type-2 diabetes on this relationship. The association of <italic>UCP2 </italic>with baseline biochemical and hormonal measurements, including levels of the inflammatory marker myeloperoxidase, was also examined.</p></sec><sec sec-type="methods"><title>Methods</title><p>UCP2 G-866A genotypes were determined using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) protocol. Myeloperoxidase levels were measured in plasma samples taken from 419 cohort patients 24&#x02013;96 hours after admission.</p></sec><sec><title>Results</title><p>Genotypes were obtained for 901 patients with genotype frequencies AA 15.5%, GA 45.5%, and GG 39.0%. Genotype was not associated with survival in the overall cohort (mortality: AA 15.6%, GA 16.8%, GG 19.4%, p = 0.541). However, amongst diabetics, AA and GA genotype groups had significantly worse survival than GG diabetic patients (p &#x0003c; 0.05) with an attributable risk of 23.3% and 18.7% for those of AA and GA genotype respectively. Multivariate analysis using a Cox proportional hazards model confirmed that the interaction of diabetes with genotype was significantly predictive of survival (p = 0.031). In the cohort's diabetic subgroup AA/GA patients had higher myeloperoxidase levels than their GG counterparts (GA/AA, n = 51, 63.9 &#x000b1; 5.23; GG, n = 34, 49.1 &#x000b1; 3.72 ng/ml, p = 0.041). Further analysis showed that this phenomenon was confined to male patients (GA/AA, n = 36, 64.3 &#x000b1; 6.23; GG, n = 29, 44.9 &#x000b1; 3.72 ng/ml, p = 0.015).</p></sec><sec><title>Conclusion</title><p>Diabetic patients in this post-myocardial infarction cohort with UCP2 -866 AA/GA genotype have poorer survival and higher myeloperoxidase levels than their GG counterparts.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Uncoupling protein 2 (UCP2) is expressed ubiquitously and is believed to dissipate the proton motive force across the inner mitochondrial membrane [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. While UCP1 may play a role in thermogenesis [<xref ref-type="bibr" rid="B3">3</xref>], UCP2 may regulate inflammation and apoptosis, and inhibition of the mitochondrial production of reactive oxygen species (ROS) [<xref ref-type="bibr" rid="B4">4</xref>]. These functions have important implications for brain and heart disease. experimental inhibition of <italic>UCP2 </italic>expression increases ROS formation [<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>], a risk factor for atherosclerosis [<xref ref-type="bibr" rid="B7">7</xref>]. UCP2 has recently been shown to mediate some of the actions of ghrelin [<xref ref-type="bibr" rid="B8">8</xref>], a circulating hormone elevated during fasting and with known actions on the heart [<xref ref-type="bibr" rid="B9">9</xref>].</p><p>Polymorphisms in the <italic>UCP2 </italic>gene have been associated with obesity [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B12">12</xref>], hypertension [<xref ref-type="bibr" rid="B13">13</xref>], and diabetes [<xref ref-type="bibr" rid="B14">14</xref>]. A common variant in the promoter of the human <italic>UCP2 </italic>gene (G-866A, rs659366)[<xref ref-type="bibr" rid="B11">11</xref>] has been associated with differential <italic>UCP2 </italic>expression [<xref ref-type="bibr" rid="B12">12</xref>] and elevated levels of markers of oxidative stress amongst diabetics [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. The A allele has been associated with enhanced <italic>UCP2 </italic>expression in adipose tissue in vivo[<xref ref-type="bibr" rid="B11">11</xref>]. Indeed, in a prospective study of 2695 men, those with -866AA genotype exhibited a greater prevalence of obesity and hypertension, and a shorter time to first coronary heart disease (CHD) event. This risk was amplified fourfold in diabetic -866AA men [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>The enzyme myeloperoxidase (MPO, EC 1.11.1.7) is mainly released by activated neutrophils with pro-oxidative and pro-inflammatory properties. Given the role of inflammation in atherogenesis, MPO is a biomarker of coronary artery disease [<xref ref-type="bibr" rid="B17">17</xref>]. Meanwhile, infiltrating macrophages and neutrophils play a role in the destabilization of coronary artery plaques and thus in the pathogenesis of acute coronary syndromes including myocardial infarction (MI)[<xref ref-type="bibr" rid="B18">18</xref>].</p><p>We thus hypothesized that the <italic>UCP2 </italic>G-866A polymorphism might be associated with survival in a study sample at high risk of future cardiovascular events, and that this relationship might be stronger amongst diabetics. Given the proinflammatory role of UCP2 [<xref ref-type="bibr" rid="B4">4</xref>], we also sought association of <italic>UCP2 </italic>genotype with plasma MPO levels in this group.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Population</title><p>Patients were admitted to Christchurch Hospital between November 1994 and June 2001 and recruited to the Christchurch Post-Myocardial Infarction (PMI) study using criteria described previously [<xref ref-type="bibr" rid="B19">19</xref>]. Briefly, MI was defined by typical ischemic symptoms, ischemic change (including ST-elevation or depression or dynamic T-wave changes, i.e. includes ST-elevation, non-ST-elevation, Q-wave, and non-Q-wave infarcts) in two or more electrocardiogram leads and peak elevation of plasma creatine kinase (CK) to at least twice the upper limit of normal. All patients were troponin-T positive. Inclusion criteria included age &#x0003c;80 years, absence of immediate heart failure or cardiogenic shock, and survival for at least 24 h after the onset of symptoms associated with MI. Patients were followed for 5 years and data on mortality/survival for the full 5 years of follow-up was available for all patients in the cohort. Blood samples and cardiac imaging were obtained 24&#x02013;96 h after symptom onset. Clinical events were determined from recruitment questionnaires, planned follow-up clinic visits, patient notes, the New Zealand National Health Information Service and hospital Patient Management System databases. Ethnicity was self-declared and was grouped as those of European, Maori, Not Stated and Other (Asian, African and Pacific Islanders) ancestry. The investigation conforms to the principles outlined in the Declaration of Helsinki and was approved by the Canterbury Ethics Committee. All participating patients provided written, informed consent.</p></sec><sec><title>Dna Extraction and Genotyping</title><p>Genomic DNA was extracted from whole blood as previously described [<xref ref-type="bibr" rid="B20">20</xref>]. DNA (100 ng) was amplified for the <italic>UCP2 </italic>G-866A PCR-RFLP assay, in which 360 bp amplimers were digested for 16 h at 37&#x000b0;C using 2.5 U of <italic>Mlu</italic>I [<xref ref-type="bibr" rid="B11">11</xref>]. The digested, gel-electrophoresed fragments were visualized using a Bio-Rad Fluor-S&#x02122; imaging system.</p></sec><sec><title>Neurohormone, Analyte and Cardiac Imaging Measurements</title><p>Circulating levels of endothelin-1, ANP and B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NTproBNP) were assayed as previously described [<xref ref-type="bibr" rid="B19">19</xref>]. creatinine clearance was calculated using the Cockcroft-Gault formula [<xref ref-type="bibr" rid="B21">21</xref>]. Levels of creatine kinase (CK) were measured using ELISA kits (Roche Diagnostics, Auckland, NZ). Left ventricular function was assessed by radionuclide ventriculography &#x02013; within 24&#x02013;96 hours of onset of MI (within 24 hours of blood sampling) [<xref ref-type="bibr" rid="B22">22</xref>]. Myeloperoxidase (EC 1.11.1.7) was measured by sandwich ELISA on plasma diluted 1:10, with a monoclonal antibody (Abcam, Cambridge, United Kingdom) and a rabbit polyclonal antibody produced in-house [<xref ref-type="bibr" rid="B23">23</xref>], with a detection range of 0.3 to 25 ng/ml and coefficient of variance of 13.8%.</p></sec><sec><title>Statistical Analysis</title><p>Univariate analysis, relating <italic>UCP2 </italic>G-866A genotype status to other variables, was performed using &#x003c7;<sup>2 </sup>and ANOVA tests. Skewed data (notably plasma hormones) were log-transformed. Survival was assessed using Kaplan-Meier survival curves and log-rank tests. Due to the small number of <italic>UCP2 </italic>-866 AA patients for which MPO levels were available data for AA and GA patients was grouped for this analysis. A Cox proportional hazard model was used to investigate independent risk factors for all-cause mortality. The model included established predictors of prognosis (age, gender, NTproBNP and CK levels, admission left ventricular ejection fraction (LVEF), &#x003b2;-blocker treatment, and creatinine clearance) [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>]. Statistical significance was deemed to be achieved at the p &#x0003c; 0.05 level. The statistical power of the study was estimated from the cohort's likely genotype split of ~15% (AA) and ~42.5% (GG or GA respectively)[<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B15">15</xref>] with a total n of ~900 and an event (mortality) rate of approximately 3% per annum and complete follow-up to 5 years. Thus there was 80% power to detect &#x0003e;10% difference in mortality between the two homozygote groups, using a two-tailed &#x003c7;<sup>2 </sup>test, &#x003b1; = 0.05. All analyses were performed using SPSS version 16.</p></sec></sec><sec><title>Results</title><sec><title>Baseline Characteristics and UCP2 Genotyping</title><p>Of an available cohort of 982, genotypes were obtained for 901 patients with genotype frequencies AA 15.5%, GA 45.5%, and GG 39.0% which did not deviate from the Hardy-Weinberg equilibrium (p = 0.999). The minor allele (A) frequency was 0.38, similar to that reported elsewhere [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B15">15</xref>]. Baseline characteristics stratified by <italic>UCP2 </italic>G-866A genotype group are shown in Table <xref ref-type="table" rid="T1">1</xref>, and did not differ from those in whom genotyping was not possible. Only patient gender was significantly associated with genotype, with the proportion of males increasing with the number of G alleles. Ethnicity was not significantly associated with differences in genotype frequency (minor allele frequencies: European 0.375, Maori 0.438, Not Stated 0.442, Other 0.371, p = 0.481).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Baseline characteristics, drug treatment and neurohormonal data stratified by UCP2 genotype group.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="7"><bold>UCP2 Genotype</bold></td></tr><tr><td></td><td align="center"><bold>n</bold></td><td align="center"><bold>AA</bold></td><td align="center"><bold>n</bold></td><td align="center"><bold>GA</bold></td><td align="center"><bold>n</bold></td><td align="center"><bold>GG</bold></td><td align="center"><bold><italic>p</italic></bold></td></tr></thead><tbody><tr><td align="left">Gender (M/F)</td><td align="center">140</td><td align="center">102/38(72.9%M)</td><td align="center">410</td><td align="center">309/101(75.4%M)</td><td align="center">351</td><td align="center">292/59 (83.2%M)</td><td align="center">0.009</td></tr><tr><td align="left">Age (years)*</td><td align="center">140</td><td align="center">61.5 &#x000b1; 0.94</td><td align="center">410</td><td align="center">62.0 &#x000b1; 0.49</td><td align="center">350</td><td align="center">62.7 &#x000b1; 057</td><td align="center">0.404</td></tr><tr><td align="left">BMI* (kgm<sup>-2</sup>)</td><td align="center">92</td><td align="center">27.2 &#x000b1; 0.51</td><td align="center">285</td><td align="center">26.9 &#x000b1; 0.25</td><td align="center">239</td><td align="center">26.4 &#x000b1; 0.25</td><td align="center">0.174</td></tr><tr><td align="left">LVEF</td><td align="center">113</td><td align="center">47.2 &#x000b1; 1.00</td><td align="center">348</td><td align="center">48.0 &#x000b1; 0.64</td><td align="center">288</td><td align="center">47.9 &#x000b1; 0.72</td><td align="center">0.822</td></tr><tr><td align="left">Predischarge Mean arterial pressure (mmHg)</td><td align="center">133</td><td align="center">82.9 &#x000b1; 0.87</td><td align="center">397</td><td align="center">83.2 &#x000b1; 0.55</td><td align="center">341</td><td align="center">84.6 &#x000b1; 0.61</td><td align="center">0.145</td></tr><tr><td align="left">Predischarge Systolic Blood pressure (mmHg)</td><td align="center">133</td><td align="center">117 &#x000b1; 1.28</td><td align="center">397</td><td align="center">116 &#x000b1; 0.81</td><td align="center">341</td><td align="center">118 &#x000b1; 0.90</td><td align="center">0.163</td></tr><tr><td align="left">Predischarge Diastolic Blood pressure (mmHg)(mmHg)</td><td align="center">133</td><td align="center">65.9 &#x000b1; 0.82</td><td align="center">397</td><td align="center">66.8 &#x000b1; 0.54</td><td align="center">341</td><td align="center">67.8 &#x000b1; 0.57</td><td align="center">0.176</td></tr><tr><td align="left"><italic>History</italic></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Previous myocardial infarction*</td><td align="center">127</td><td align="center">24(18.9%)</td><td align="center">389</td><td align="center">72 (18.5%)</td><td align="center">334</td><td align="center">58 (17.4%)</td><td align="center">0.896</td></tr><tr><td align="left">&#x02003;hypertension *</td><td align="center">129</td><td align="center">47(36.4%)</td><td align="center">400</td><td align="center">157 (39.3%)</td><td align="center">342</td><td align="center">131 (38.3%)</td><td align="center">0.847</td></tr><tr><td align="left">&#x02003;Type 2 Diabetes*</td><td align="center">139</td><td align="center">22(15.8%)</td><td align="center">409</td><td align="center">48(11.7%)</td><td align="center">349</td><td align="center">38 (10.9%)</td><td align="center">0.308</td></tr><tr><td align="left">&#x02003;Predischarge Atrial Fibrillation*<break/>Fibrillation*</td><td align="center">112</td><td align="center">12(10.7%)</td><td align="center">346</td><td align="center">35 (10.1%)</td><td align="center">297</td><td align="center">47 (15.8%)</td><td align="center">0.076</td></tr><tr><td align="left">&#x02003;Predischarge Ventricular Fibrillation* Fibrillation*</td><td align="center">113</td><td align="center">11(9.7%)</td><td align="center">355</td><td align="center">40 11.3%)</td><td align="center">300</td><td align="center">21 (7.0%)</td><td align="center">0.173</td></tr><tr><td align="left"><italic>Laboratory Data</italic></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Total Cholesterol* (mmol/l)</td><td align="center">130</td><td align="center">5.94 &#x000b1; 0.10</td><td align="center">376</td><td align="center">5.95 &#x000b1; 0.065</td><td align="center">330</td><td align="center">5.81 &#x000b1; 0.068</td><td align="center">0.325</td></tr><tr><td align="left">&#x02003;HDL Cholesterol* (mmol/l)</td><td align="center">129</td><td align="center">1.16 &#x000b1; 0.026</td><td align="center">371</td><td align="center">1.16 &#x000b1; 0.017</td><td align="center">325</td><td align="center">1.15 &#x000b1; 0.018</td><td align="center">0.913</td></tr><tr><td align="left">&#x02003;LDL Cholesterol* (mmol/l)</td><td align="center">97</td><td align="center">3.96 &#x000b1; 0.10</td><td align="center">299</td><td align="center">3.98 &#x000b1; 0.058</td><td align="center">268</td><td align="center">3.83 &#x000b1; 0.069</td><td align="center">0.225</td></tr><tr><td align="left">&#x02003;Triglycerides* (mmol/l)</td><td align="center">130</td><td align="center">2.02 &#x000b1; 0.11</td><td align="center">376</td><td align="center">2.08 &#x000b1; 0.096</td><td align="center">330</td><td align="center">2.01 &#x000b1; 0.069</td><td align="center">0.791</td></tr><tr><td align="left">&#x02003;Plasma Creatinine&#x02020; (&#x003bc;mol/l)</td><td align="center">136</td><td align="center">83 (79&#x02013;87)</td><td align="center">405</td><td align="center">85 (82&#x02013;87)</td><td align="center">347</td><td align="center">85 (83&#x02013;87)</td><td align="center">0.600</td></tr><tr><td align="left">&#x02003;Creatinine Clearance* (ml/s)</td><td align="center">99</td><td align="center">1.28 &#x000b1; 0.047</td><td align="center">308</td><td align="center">1.28 &#x000b1; 0.023</td><td align="center">267</td><td align="center">1.32 &#x000b1; 0.028</td><td align="center">0.546</td></tr><tr><td align="left">&#x02003;Peak Creatine kinase&#x02020; (units/l)</td><td align="center">105</td><td align="center">1440(1250&#x02013;1660)</td><td align="center">327</td><td align="center">1610(1480&#x02013;1740)</td><td align="center">269</td><td align="center">1640(1510&#x02013;1680)</td><td align="center">0.304</td></tr><tr><td align="left">&#x02003;Plasma Glucose (mmol/l)</td><td align="center">137</td><td align="center">8.55 &#x000b1; 0.27</td><td align="center">404</td><td align="center">8.64 &#x000b1; 0.15</td><td align="center">344</td><td align="center">8.55 &#x000b1; 0.16</td><td align="center">0.912</td></tr><tr><td align="left">&#x02003;Glycated Hemoglobin %</td><td align="center">105</td><td align="center">6.07 &#x000b1; 0.11</td><td align="center">324</td><td align="center">6.06 &#x000b1; 0.06</td><td align="center">274</td><td align="center">6.03 &#x000b1; 0.06</td><td align="center">0.905</td></tr><tr><td align="left"><italic>Discharge Medications</italic></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;ACE inhibitor *</td><td align="center">122</td><td align="center">36(29.5%)</td><td align="center">374</td><td align="center">121 (32.4%)</td><td align="center">318</td><td align="center">109 (34.3%)</td><td align="center">0.624</td></tr><tr><td align="left">&#x02003;&#x003b2;-blocker *</td><td align="center">122</td><td align="center">78(63.9%)</td><td align="center">374</td><td align="center">232 (62.0%)</td><td align="center">318</td><td align="center">176 (55.3%)</td><td align="center">0.119</td></tr><tr><td align="left">Neurohormonal Data</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;ANP (pmol/l)&#x02021;</td><td align="center">138</td><td align="center">26.8(24.4&#x02013;29.4)</td><td align="center">403</td><td align="center">28.5(27.0&#x02013;30.0)</td><td align="center">346</td><td align="center">28.8(27.1&#x02013;30.6)</td><td align="center">0.406</td></tr><tr><td align="left">&#x02003;BNP (pmol/l)&#x02021;</td><td align="center">138</td><td align="center">18.2(16.4&#x02013;20.2)</td><td align="center">404</td><td align="center">19.8(18.7&#x02013;21.0)</td><td align="center">346</td><td align="center">19.9(18.8&#x02013;21.1)</td><td align="center">0.290</td></tr><tr><td align="left">&#x02003;NTproBNP (pmol/l)&#x02021;</td><td align="center">137</td><td align="center">98.6(87.0&#x02013;112)</td><td align="center">399</td><td align="center">112(104&#x02013;121)</td><td align="center">344</td><td align="center">111(103&#x02013;121)</td><td align="center">0.200</td></tr><tr><td align="left">&#x02003;Endothelin-1 (pmol/l)&#x02021;</td><td align="center">137</td><td align="center">1.64(1.52&#x02013;1.77)</td><td align="center">398</td><td align="center">1.80(1.73&#x02013;1.88)</td><td align="center">340</td><td align="center">1.76(1.167&#x02013;1.81)</td><td align="center">0.110</td></tr></tbody></table><table-wrap-foot><p>*Means (SEM) or occurrence (percentage); &#x02020;Median (range); &#x02021;Geometric mean (95% confidence interval).</p></table-wrap-foot></table-wrap></sec><sec><title>Survival and UCP2 Genotype</title><p>A total of 159 deaths were recorded in the study cohort during the 5-year follow-up. <italic>UCP2 </italic>G-866A genotype was not associated with survival in the overall cohort (mortality: AA 15.6%, GA 16.8%, GG 19.4%, p = 0.541). However when the cohort was stratified according to prior diagnosis of type-2 diabetes, genotype was significantly associated with survival amongst diabetic patients (Figure <xref ref-type="fig" rid="F1">1</xref>). Diabetic patients of AA or GA genotype had significantly worse survival than GG diabetic patients (p &#x0003c; 0.05), with an attributable risk of 23.3% and 18.7% respectively. Multivariate analysis using a Cox proportional hazards model confirmed that <italic>UCP2 </italic>G-866A genotype alone was not a significant predictor of survival in the cohort, although there were trends in that direction (Table <xref ref-type="table" rid="T2">2</xref>). However the interaction of diabetes with genotype was significantly predictive of survival in a model including age, gender, NTproBNP and CK levels, left ventricular ejection fraction, creatinine clearance, ethnicity, &#x003b2;-blocker treatment, diabetes and genotype (Table <xref ref-type="table" rid="T2">2</xref>). Inclusion of additional covariates to the multivariate model did not add significantly to it (e.g. baseline total cholesterol Hazard Ratio = 1.17 [0.96&#x02013;1.43] p = 0.131; mean arterial pressure HR = 1.01 [0.99&#x02013;1.04] p = 0.240) and exceeded the recommended number of predictors given the number of events in the analysis.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>A Kaplan-Meier survival curve indicating differences in survival after MI for UCP2 G-866A genotype groups in A) non-diabetic patients and B) diabetic patients</bold>.</p></caption><graphic xlink:href="1475-2840-8-31-1"/></fig><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Cox's proportional hazards regression model for mortality in the PMI cohort.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Coefficient</td><td align="center">SE</td><td align="center">Wald</td><td align="center">df</td><td align="center">Significance</td><td align="center">Hazard Ratio</td><td align="center">95% CI for Hazard Ratio</td></tr></thead><tbody><tr><td align="left">Age</td><td align="center">0.018</td><td align="center">0.016</td><td align="center">1.40</td><td align="center">1</td><td align="center">0.237</td><td align="center">1.02</td><td align="center">0.99&#x02013;1.05</td></tr><tr><td align="left">Gender</td><td align="center">0.587</td><td align="center">0.270</td><td align="center">4.71</td><td align="center">1</td><td align="center">0.030</td><td align="center">1.80</td><td align="center">1.06&#x02013;3.06</td></tr><tr><td align="left">ACE inhibitor (No/Yes)</td><td align="center">0.235</td><td align="center">0.229</td><td align="center">1.06</td><td align="center">1</td><td align="center">0.303</td><td align="center">1.27</td><td align="center">0.81&#x02013;1.98</td></tr><tr><td align="left">LVEF (1&#x02013;4 days post-MI)</td><td align="center">-0.013</td><td align="center">0.011</td><td align="center">1.48</td><td align="center">1</td><td align="center">0.224</td><td align="center">0.99</td><td align="center">0.97&#x02013;1.01</td></tr><tr><td align="left">Log<sub>10 </sub>NTproBNP*</td><td align="center">1.55</td><td align="center">0.409</td><td align="center">14.3</td><td align="center">1</td><td align="center">&#x0003c;0.001</td><td align="center">4.70</td><td align="center">2.11&#x02013;10.5</td></tr><tr><td align="left">Log<sub>10 </sub>peak creatine kinase*</td><td align="center">1.11</td><td align="center">0.338</td><td align="center">10.8</td><td align="center">1</td><td align="center">0.001</td><td align="center">3.04</td><td align="center">1.56&#x02013;5.88</td></tr><tr><td align="left">Creatinine clearance</td><td align="center">-0.900</td><td align="center">0.384</td><td align="center">5.49</td><td align="center">1</td><td align="center">0.019</td><td align="center">0.406</td><td align="center">0.19&#x02013;0.86</td></tr><tr><td align="left">Ethnicity (European v non-European)</td><td align="center">1.05</td><td align="center">0.597</td><td align="center">3.11</td><td align="center">1</td><td align="center">0.078</td><td align="center">2.86</td><td align="center">0.89&#x02013;9.21</td></tr><tr><td align="left">Type 2 Diabetes</td><td align="center">0.847</td><td align="center">0.602</td><td align="center">1.98</td><td align="center">1</td><td align="center">0.159</td><td align="center">2.33</td><td align="center">0.72&#x02013;7.59</td></tr><tr><td align="left">UCP2 G-866A genotype</td><td></td><td></td><td align="center">4.91</td><td align="center">2</td><td align="center">0.086</td><td></td><td></td></tr><tr><td align="left">&#x02003;GG v AA</td><td align="center">1.64</td><td align="center">0.747</td><td align="center">4.79</td><td align="center">1</td><td align="center">0.029</td><td align="center">5.13</td><td align="center">1.19&#x02013;22.2</td></tr><tr><td align="left">&#x02003;GG v GA</td><td align="center">1.16</td><td align="center">0.684</td><td align="center">2.89</td><td align="center">1</td><td align="center">0.089</td><td align="center">3.19</td><td align="center">0.841&#x02013;12.2</td></tr><tr><td align="left">Diabetes &#x000d7; UCP2 genotype</td><td></td><td></td><td align="center">6.92</td><td align="center">2</td><td align="center">0.031</td><td></td><td></td></tr><tr><td align="left">&#x02003;Diabetes &#x000d7; UCP2 genotype(GG v AA)</td><td align="center">1.52</td><td align="center">0.725</td><td align="center">4.40</td><td align="center">1</td><td align="center">0.036</td><td align="center">4.59</td><td align="center">1.10&#x02013;18.9</td></tr><tr><td align="left">&#x02003;Diabetes &#x000d7; UCP2 genotype(GG v GA)</td><td align="center">2.09</td><td align="center">0.826</td><td align="center">6.40</td><td align="center">1</td><td align="center">0.011</td><td align="center">8.06</td><td align="center">1.60&#x02013;40.0</td></tr></tbody></table><table-wrap-foot><p>* Hazard Ratio represents the change in risk for every 10-fold increase in measurement level.</p></table-wrap-foot></table-wrap></sec><sec><title>UCP2 Genotype and Plasma Myeloperoxidase Levels</title><p>Plasma MPO levels were available from samples taken from 419 patients in the cohort 24&#x02013;96 hours after admission. These patients were selected only by the availability of adequate stored plasma for the measurement of MPO and we believe this selection was essentially random. Whilst there was no overall association of <italic>UCP2 </italic>genotype, diabetic status or gender with MPO levels, there was a significant interaction of gender*diabetic status*<italic>UCP2 </italic>genotype in a univariate general linear model (p = 0.037). In the diabetic subgroup of the cohort, patients with at least one A allele had significantly higher MPO levels than their GG counterparts (GA/AA, n = 51, 63.9 &#x000b1; 5.23 ng/ml; GG, n = 34, 49.1 &#x000b1; 3.72 ng/ml, p = 0.041; Figure <xref ref-type="fig" rid="F2">2</xref>). This phenomenon was only apparent in male patients (GA/AA, n = 36, 64.3 &#x000b1; 6.23 ng/ml; GG, n = 29, 44.9 &#x000b1; 3.72 ng/ml, p = 0.015; Figure <xref ref-type="fig" rid="F2">2</xref>). There was no significant association between genotype and MPO levels in female diabetic patients (GA/AA, n = 15, 62.9 &#x000b1; 9.99 ng/ml; GG, n = 5, 73.5 &#x000b1; 6.17 ng/ml, p = 0.561) or amongst non-diabetic patients (data not shown). MPO levels did not differ significantly between diabetic and non-diabetic patients (diabetics, n = 85, 58.0 &#x000b1; 3.27 ng/ml; non-diabetics, n = 334, 63.7 &#x000b1; 2.21 ng/ml, p = 0.223).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Plasma myeloperoxidase levels 24&#x02013;96 hours after index patient admission stratified by UCP2 G-866A genotype and diabetic status a) Male and Female patients, b) Male patients</bold>. N = non-diabetic, Y = diabetic. Stars and circles indicate outlying data.</p></caption><graphic xlink:href="1475-2840-8-31-2"/></fig></sec></sec><sec><title>Discussion</title><p>The major finding of this study is that the interaction between type-2 diabetes and <italic>UCP2 </italic>G-866A genotype was significantly associated with survival in a cohort of post-MI patients. The <italic>UCP2</italic>-866A allele carriers had significantly worse survival during 5 years of follow-up post-MI than GG patients if they were diabetic. These data extend previous observations amongst otherwise healthy men in whom the <italic>UCP2 </italic>G-866A genotype was associated with future risk of CHD events, both in those individuals devoid of traditional risk factors for cardiovascular disease and amongst the small proportion of diabetic patients [<xref ref-type="bibr" rid="B15">15</xref>]. In contrast a study of 3122 type-2 diabetic patients reported association of the <italic>UCP2 </italic>-866 A allele with decreased risk of incident coronary artery disease, including sudden cardiac death [<xref ref-type="bibr" rid="B26">26</xref>]. The disease-free survival profile in this report closely resembles the survival curve for non-diabetic patients in our study (Figure <xref ref-type="fig" rid="F1">1A</xref>). This inconsistency may have several explanations: study endpoints differed (survival versus disease-free survival) and differing age and ethnic profiles.</p><p>Diabetes is associated with increased oxidative stress [<xref ref-type="bibr" rid="B27">27</xref>] and diabetic patients with the <italic>UCP2</italic>-866AA genotype and CHD have been shown to have lower total antioxidant status and higher levels of plasma F2-isoprostanes [<xref ref-type="bibr" rid="B15">15</xref>]. Elevated levels of plasma MPO, has previously been shown to be a predictor of mortality in the cohort studied in this report [<xref ref-type="bibr" rid="B28">28</xref>]. The difference observed in MPO levels between GA/AA and GG diabetic patients was of similar magnitude to that observed between heart healthy control subjects and PMI patients in the previous report [<xref ref-type="bibr" rid="B28">28</xref>]. We did not include MPO as a predictor in the multivariate model of survival as missing data would have severely restricted the number of patients in the analysis. While this data was not well powered to detect differences in MPO levels based on UCP2 genotypes groups, we did detect an association of MPO levels and genotype amongst diabetic patients in this study. This was particularly evident in male diabetic patients in the cohort, a finding consistent with previous reports of gender specific differences in oxidative stress [<xref ref-type="bibr" rid="B29">29</xref>,<xref ref-type="bibr" rid="B30">30</xref>]. This finding of an association between UCP2 G-866A genotype and plasma MPO levels can be regarded as hypothesis generating and requires validation in other studies.</p><p>Although the current study has considerable statistical power, due to the size of the cohort, the length of follow-up, the number of clinical endpoints recorded and the minor allele frequency of the G-866A polymorphism, statistically significant differences may have occurred by chance and weak associations may have been missed. Missing data for some parameters has limited the power of this study to investigate their association with genotype. The study cohort was dominated by ethnic Europeans and the results should not be extrapolated to other populations.</p></sec><sec><title>Conclusion</title><p>Our data provide support for the idea that modulation of UCP2 expression might be an important novel target for reducing cardiovascular morbidity and mortality, particularly amongst diabetic patients [<xref ref-type="bibr" rid="B31">31</xref>]. A growing body of evidence supports the UCP2 G-866A polymorphism as a marker of cardiovascular risk [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B32">32</xref>]. This study extends this evidence to include UCP2 genotype as a potential marker of prognosis in type-2 diabetes patients following acute MI.</p></sec><sec><title>Abbreviations</title><p>UCP2: uncoupling protein 2 gene; ROS: reactive oxygen species; MPO: myeloperoxidase; PMI: Post-Myocardial Infarction; BNP: B-type natriuretic peptide; NTproBNP: N-terminal pro-BNP; CK: creatine kinase; LVEF: left ventricular ejection fraction; CHD: coronary heart disease.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>BRP, SSD and HEM conceived the study and the experimental design and BRP, CLD and TJM performed the data acquisition and interpreted the results. TGY was responsible for hormone assay data acquisition and interpretation. BRP, CMF and HEM drafted the manuscript. APP, VAC, AMR, CCW, LS, SSD and HEM interpreted the results and critically reviewed the manuscript adding important intellectual content. All authors read and approved the final version of the manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank the participants in the PMI study, Endolab and Christchurch Cardiology Outpatient staff. The Health Research Council and the National Heart Foundation (NHF) of New Zealand supported this work. CLD participated in the Butler-IFSA study abroad program at the University of Canterbury, Christchurch. APP held a Foundation of Research, Science and Technology Postdoctoral Fellowship and AMR held the NHF Chair of Cardiovascular Studies.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fleury</surname><given-names>C</given-names></name><name><surname>Neverova</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name><name><surname>Raimbault</surname><given-names>S</given-names></name><name><surname>Champigny</surname><given-names>O</given-names></name><name><surname>Levi-Meyrueis</surname><given-names>C</given-names></name><name><surname>Bouillaud</surname><given-names>F</given-names></name><name><surname>Seldin</surname><given-names>MF</given-names></name><name><surname>Surwit</surname><given-names>RS</given-names></name><name><surname>Ricquier</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia</article-title><source>Nature genetics</source><year>1997</year><volume>15</volume><fpage>269</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">9054939</pub-id><pub-id pub-id-type="doi">10.1038/ng0397-269</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garlid</surname><given-names>KD</given-names></name><name><surname>Jaburek</surname><given-names>M</given-names></name><name><surname>Jezek</surname><given-names>P</given-names></name></person-group><article-title>Mechanism of uncoupling protein action</article-title><source>Biochem Soc Trans</source><year>2001</year><volume>29</volume><fpage>803</fpage><lpage>806</lpage><pub-id pub-id-type="pmid">11709078</pub-id><pub-id pub-id-type="doi">10.1042/BST0290803</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brand</surname><given-names>MD</given-names></name><name><surname>Esteves</surname><given-names>TC</given-names></name></person-group><article-title>Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3</article-title><source>Cell Metab</source><year>2005</year><volume>2</volume><fpage>85</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">16098826</pub-id><pub-id pub-id-type="doi">10.1016/j.cmet.2005.06.002</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mattiasson</surname><given-names>G</given-names></name><name><surname>Sullivan</surname><given-names>PG</given-names></name></person-group><article-title>The emerging functions of UCP2 in health, disease, and therapeutics</article-title><source>Antioxid Redox Signal</source><year>2006</year><volume>8</volume><fpage>1</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">16487034</pub-id><pub-id pub-id-type="doi">10.1089/ars.2006.8.1</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duval</surname><given-names>C</given-names></name><name><surname>Negre-Salvayre</surname><given-names>A</given-names></name><name><surname>Dogilo</surname><given-names>A</given-names></name><name><surname>Salvayre</surname><given-names>R</given-names></name><name><surname>Penicaud</surname><given-names>L</given-names></name><name><surname>Casteilla</surname><given-names>L</given-names></name></person-group><article-title>Increased reactive oxygen species production with antisense oligonucleotides directed against uncoupling protein 2 in murine endothelial cells</article-title><source>Biochem Cell Biol</source><year>2002</year><volume>80</volume><fpage>757</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">12555808</pub-id><pub-id pub-id-type="doi">10.1139/o02-158</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arsenijevic</surname><given-names>D</given-names></name><name><surname>Onuma</surname><given-names>H</given-names></name><name><surname>Pecqueur</surname><given-names>C</given-names></name><name><surname>Raimbault</surname><given-names>S</given-names></name><name><surname>Manning</surname><given-names>BS</given-names></name><name><surname>Miroux</surname><given-names>B</given-names></name><name><surname>Couplan</surname><given-names>E</given-names></name><name><surname>Alves-Guerra</surname><given-names>MC</given-names></name><name><surname>Goubern</surname><given-names>M</given-names></name><name><surname>Surwit</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production</article-title><source>Nature genetics</source><year>2000</year><volume>26</volume><fpage>435</fpage><lpage>439</lpage><pub-id pub-id-type="pmid">11101840</pub-id><pub-id pub-id-type="doi">10.1038/82565</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blanc</surname><given-names>J</given-names></name><name><surname>Alves-Guerra</surname><given-names>MC</given-names></name><name><surname>Esposito</surname><given-names>B</given-names></name><name><surname>Rousset</surname><given-names>S</given-names></name><name><surname>Gourdy</surname><given-names>P</given-names></name><name><surname>Ricquier</surname><given-names>D</given-names></name><name><surname>Tedgui</surname><given-names>A</given-names></name><name><surname>Miroux</surname><given-names>B</given-names></name><name><surname>Mallat</surname><given-names>Z</given-names></name></person-group><article-title>Protective role of uncoupling protein 2 in atherosclerosis</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>388</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">12551860</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000051722.66074.60</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andrews</surname><given-names>ZB</given-names></name><name><surname>Liu</surname><given-names>Z-W</given-names></name><name><surname>Walllingford</surname><given-names>N</given-names></name><name><surname>Erion</surname><given-names>DM</given-names></name><name><surname>Borok</surname><given-names>E</given-names></name><name><surname>Friedman</surname><given-names>JM</given-names></name><name><surname>Tschop</surname><given-names>MH</given-names></name><name><surname>Shanabrough</surname><given-names>M</given-names></name><name><surname>Cline</surname><given-names>G</given-names></name><name><surname>Shulman</surname><given-names>GI</given-names></name><etal></etal></person-group><article-title>UCP2 mediates ghrelin/'s action on NPY/AgRP neurons by lowering free radicals</article-title><source>Nature</source><year>2008</year><volume>454</volume><fpage>846</fpage><lpage>851</lpage><pub-id pub-id-type="pmid">18668043</pub-id><pub-id pub-id-type="doi">10.1038/nature07181</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pemberton</surname><given-names>CJ</given-names></name><name><surname>Tokola</surname><given-names>H</given-names></name><name><surname>Bagi</surname><given-names>Z</given-names></name><name><surname>Koller</surname><given-names>A</given-names></name><name><surname>Pontinen</surname><given-names>J</given-names></name><name><surname>Ola</surname><given-names>A</given-names></name><name><surname>Vuolteenaho</surname><given-names>O</given-names></name><name><surname>Szokodi</surname><given-names>I</given-names></name><name><surname>Ruskoaho</surname><given-names>H</given-names></name></person-group><article-title>Ghrelin induces vasoconstriction in the rat coronary vasculature without altering cardiac peptide secretion</article-title><source>American journal of physiology</source><year>2004</year><volume>287</volume><fpage>H1522</fpage><lpage>1529</lpage><pub-id pub-id-type="pmid">15142846</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ochoa</surname><given-names>MC</given-names></name><name><surname>Santos</surname><given-names>JL</given-names></name><name><surname>Azcona</surname><given-names>C</given-names></name><name><surname>Moreno-Aliaga</surname><given-names>MJ</given-names></name><name><surname>Martinez-Gonzalez</surname><given-names>MA</given-names></name><name><surname>Martinez</surname><given-names>JA</given-names></name><name><surname>Marti</surname><given-names>A</given-names></name></person-group><article-title>Association between obesity and insulin resistance with UCP2-UCP3 gene variants in Spanish children and adolescents</article-title><source>Mol Genet Metab</source><year>2007</year><volume>92</volume><fpage>351</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17870627</pub-id><pub-id pub-id-type="doi">10.1016/j.ymgme.2007.07.011</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Esterbauer</surname><given-names>H</given-names></name><name><surname>Schneitler</surname><given-names>C</given-names></name><name><surname>Oberkofler</surname><given-names>H</given-names></name><name><surname>Ebenbichler</surname><given-names>C</given-names></name><name><surname>Paulweber</surname><given-names>B</given-names></name><name><surname>Sandhofer</surname><given-names>F</given-names></name><name><surname>Ladurner</surname><given-names>G</given-names></name><name><surname>Hell</surname><given-names>E</given-names></name><name><surname>Strosberg</surname><given-names>AD</given-names></name><name><surname>Patsch</surname><given-names>JR</given-names></name><etal></etal></person-group><article-title>A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans</article-title><source>Nature genetics</source><year>2001</year><volume>28</volume><fpage>178</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">11381268</pub-id><pub-id pub-id-type="doi">10.1038/88911</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krempler</surname><given-names>F</given-names></name><name><surname>Esterbauer</surname><given-names>H</given-names></name><name><surname>Weitgasser</surname><given-names>R</given-names></name><name><surname>Ebenbichler</surname><given-names>C</given-names></name><name><surname>Patsch</surname><given-names>JR</given-names></name><name><surname>Miller</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Linnemayr</surname><given-names>V</given-names></name><name><surname>Oberkofler</surname><given-names>H</given-names></name><name><surname>Patsch</surname><given-names>W</given-names></name></person-group><article-title>A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans</article-title><source>Diabetes</source><year>2002</year><volume>51</volume><fpage>3331</fpage><lpage>3335</lpage><pub-id pub-id-type="pmid">12401727</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.51.11.3331</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>Q</given-names></name><name><surname>Ikegami</surname><given-names>H</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Kawabata</surname><given-names>Y</given-names></name><name><surname>Ono</surname><given-names>M</given-names></name><name><surname>Nishino</surname><given-names>M</given-names></name><name><surname>Ohishi</surname><given-names>M</given-names></name><name><surname>Katsuya</surname><given-names>T</given-names></name><name><surname>Rakugi</surname><given-names>H</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>A common polymorphism of uncoupling protein 2 gene is associated with hypertension</article-title><source>J Hypertens</source><year>2004</year><volume>22</volume><fpage>97</fpage><lpage>102</lpage><pub-id pub-id-type="pmid">15106800</pub-id><pub-id pub-id-type="doi">10.1097/00004872-200401000-00018</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sesti</surname><given-names>G</given-names></name><name><surname>Cardellini</surname><given-names>M</given-names></name><name><surname>Marini</surname><given-names>MA</given-names></name><name><surname>Frontoni</surname><given-names>S</given-names></name><name><surname>D'Adamo</surname><given-names>M</given-names></name><name><surname>Del Guerra</surname><given-names>S</given-names></name><name><surname>Lauro</surname><given-names>D</given-names></name><name><surname>De Nicolais</surname><given-names>P</given-names></name><name><surname>Sbraccia</surname><given-names>P</given-names></name><name><surname>Del Prato</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects</article-title><source>Diabetes</source><year>2003</year><volume>52</volume><fpage>1280</fpage><lpage>1283</lpage><pub-id pub-id-type="pmid">12716765</pub-id><pub-id pub-id-type="doi">10.2337/diabetes.52.5.1280</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dhamrait</surname><given-names>SS</given-names></name><name><surname>Stephens</surname><given-names>JW</given-names></name><name><surname>Cooper</surname><given-names>JA</given-names></name><name><surname>Acharya</surname><given-names>J</given-names></name><name><surname>Mani</surname><given-names>AR</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>GJ</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Hurel</surname><given-names>SJ</given-names></name><name><surname>Montgomery</surname><given-names>HE</given-names></name></person-group><article-title>Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2</article-title><source>Eur Heart J</source><year>2004</year><volume>25</volume><fpage>468</fpage><lpage>475</lpage><pub-id pub-id-type="pmid">15039126</pub-id><pub-id pub-id-type="doi">10.1016/j.ehj.2004.01.007</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stephens</surname><given-names>JW</given-names></name><name><surname>Dhamrait</surname><given-names>SS</given-names></name><name><surname>Mani</surname><given-names>AR</given-names></name><name><surname>Acharya</surname><given-names>J</given-names></name><name><surname>Moore</surname><given-names>K</given-names></name><name><surname>Hurel</surname><given-names>SJ</given-names></name><name><surname>Humphries</surname><given-names>SE</given-names></name></person-group><article-title>Interaction between the uncoupling protein 2 -866G&#x0003e;A gene variant and cigarette smoking to increase oxidative stress in subjects with diabetes</article-title><source>Nutr Metab Cardiovasc Dis</source><year>2007</year><volume>18</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17555951</pub-id><pub-id pub-id-type="doi">10.1016/j.numecd.2007.01.010</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loria</surname><given-names>V</given-names></name><name><surname>Dato</surname><given-names>I</given-names></name><name><surname>Graziani</surname><given-names>F</given-names></name><name><surname>Biasucci</surname><given-names>LM</given-names></name></person-group><article-title>Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes</article-title><source>Mediators of inflammation</source><year>2008</year><volume>2008</volume><fpage>135625</fpage><pub-id pub-id-type="pmid">18382609</pub-id><pub-id pub-id-type="doi">10.1155/2008/135625</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Naruko</surname><given-names>T</given-names></name><name><surname>Ueda</surname><given-names>M</given-names></name><name><surname>Haze</surname><given-names>K</given-names></name><name><surname>Wal</surname><given-names>AC van der</given-names></name><name><surname>Loos</surname><given-names>CM van der</given-names></name><name><surname>Itoh</surname><given-names>A</given-names></name><name><surname>Komatsu</surname><given-names>R</given-names></name><name><surname>Ikura</surname><given-names>Y</given-names></name><name><surname>Ogami</surname><given-names>M</given-names></name><name><surname>Shimada</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Neutrophil infiltration of culprit lesions in acute coronary syndromes</article-title><source>Circulation</source><year>2002</year><volume>106</volume><fpage>2894</fpage><lpage>2900</lpage><pub-id pub-id-type="pmid">12460868</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000042674.89762.20</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>A</given-names></name><name><surname>Nicholls</surname><given-names>M</given-names></name><name><surname>Yandle</surname><given-names>T</given-names></name><name><surname>Ikram</surname><given-names>H</given-names></name><name><surname>Espiner</surname><given-names>E</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Buttimore</surname><given-names>R</given-names></name><name><surname>Lainchbury</surname><given-names>J</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name><name><surname>Frampton</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction</article-title><source>Heart</source><year>1999</year><volume>81</volume><fpage>114</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">9922344</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Palmer</surname><given-names>B</given-names></name><name><surname>Pilbrow</surname><given-names>A</given-names></name><name><surname>Frampton</surname><given-names>C</given-names></name><name><surname>Yandle</surname><given-names>T</given-names></name><name><surname>Nicholls</surname><given-names>M</given-names></name><name><surname>Richards</surname><given-names>A</given-names></name><name><surname>Cameron</surname><given-names>V</given-names></name></person-group><article-title>ACE gene polymorphism interacts with LVEF and BNP levels to predict mortality following myocardial infarction</article-title><source>Journal of the American College of Cardiology</source><year>2003</year><volume>41</volume><fpage>729</fpage><lpage>736</lpage><pub-id pub-id-type="pmid">12628714</pub-id><pub-id pub-id-type="doi">10.1016/S0735-1097(02)02927-3</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cockcroft</surname><given-names>DW</given-names></name><name><surname>Gault</surname><given-names>MH</given-names></name></person-group><article-title>Prediction of creatinine clearance from serum creatinine</article-title><source>Nephron</source><year>1976</year><volume>16</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">1244564</pub-id><pub-id pub-id-type="doi">10.1159/000180580</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Nicholls</surname><given-names>MG</given-names></name><name><surname>Espiner</surname><given-names>EA</given-names></name><name><surname>Lainchbury</surname><given-names>JG</given-names></name><name><surname>Troughton</surname><given-names>RW</given-names></name><name><surname>Elliott</surname><given-names>J</given-names></name><name><surname>Frampton</surname><given-names>C</given-names></name><name><surname>Turner</surname><given-names>J</given-names></name><name><surname>Crozier</surname><given-names>IG</given-names></name><name><surname>Yandle</surname><given-names>TG</given-names></name></person-group><article-title>B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>2786</fpage><lpage>2792</lpage><pub-id pub-id-type="pmid">12771003</pub-id><pub-id pub-id-type="doi">10.1161/01.CIR.0000070953.76250.B9</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cameron</surname><given-names>VA</given-names></name><name><surname>Mocatta</surname><given-names>TJ</given-names></name><name><surname>Pilbrow</surname><given-names>AP</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Troughton</surname><given-names>RW</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Winterbourn</surname><given-names>CC</given-names></name></person-group><article-title>Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure</article-title><source>Hypertension</source><year>2006</year><volume>47</volume><fpage>1155</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">16651460</pub-id><pub-id pub-id-type="doi">10.1161/01.HYP.0000222893.85662.cd</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baird</surname><given-names>TE</given-names></name><name><surname>Palmer</surname><given-names>BR</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Yandle</surname><given-names>TG</given-names></name><name><surname>Skelton</surname><given-names>L</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Cameron</surname><given-names>VA</given-names></name></person-group><article-title>Association of the aldosterone synthase gene C-344T polymorphism with risk factors and survival in a post-myocardial infarction cohort</article-title><source>J Hum Hypertens</source><year>2007</year><volume>21</volume><fpage>256</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">17215850</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>RP</given-names></name><name><surname>Palmer</surname><given-names>BR</given-names></name><name><surname>Pilbrow</surname><given-names>AP</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Troughton</surname><given-names>RW</given-names></name><name><surname>Yandle</surname><given-names>TG</given-names></name><name><surname>Skelton</surname><given-names>L</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Cameron</surname><given-names>VA</given-names></name></person-group><article-title>Evaluation of AMPD1 C34T genotype as a predictor of mortality in heart failure and post-myocardial infarction patients</article-title><source>Am Heart J</source><year>2006</year><volume>152</volume><fpage>312</fpage><lpage>320</lpage><pub-id pub-id-type="pmid">16875916</pub-id><pub-id pub-id-type="doi">10.1016/j.ahj.2005.12.015</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheurfa</surname><given-names>N</given-names></name><name><surname>Dubois-Laforgue</surname><given-names>D</given-names></name><name><surname>Ferrarezi</surname><given-names>DA</given-names></name><name><surname>Reis</surname><given-names>AF</given-names></name><name><surname>Brenner</surname><given-names>GM</given-names></name><name><surname>Bouche</surname><given-names>C</given-names></name><name><surname>Le Feuvre</surname><given-names>C</given-names></name><name><surname>Fumeron</surname><given-names>F</given-names></name><name><surname>Timsit</surname><given-names>J</given-names></name><name><surname>Marre</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The common -866G&#x0003e;A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>1063</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">18192542</pub-id><pub-id pub-id-type="doi">10.2337/db07-1292</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brownlee</surname><given-names>M</given-names></name></person-group><article-title>Biochemistry and molecular cell biology of diabetic complications</article-title><source>Nature</source><year>2001</year><volume>414</volume><fpage>813</fpage><lpage>820</lpage><pub-id pub-id-type="pmid">11742414</pub-id><pub-id pub-id-type="doi">10.1038/414813a</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mocatta</surname><given-names>TJ</given-names></name><name><surname>Pilbrow</surname><given-names>AP</given-names></name><name><surname>Cameron</surname><given-names>VA</given-names></name><name><surname>Senthilmohan</surname><given-names>R</given-names></name><name><surname>Frampton</surname><given-names>CM</given-names></name><name><surname>Richards</surname><given-names>AM</given-names></name><name><surname>Winterbourn</surname><given-names>CC</given-names></name></person-group><article-title>Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>49</volume><fpage>1993</fpage><lpage>2000</lpage><pub-id pub-id-type="pmid">17512353</pub-id><pub-id pub-id-type="doi">10.1016/j.jacc.2007.02.040</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sureda</surname><given-names>A</given-names></name><name><surname>Ferrer</surname><given-names>MD</given-names></name><name><surname>Tauler</surname><given-names>P</given-names></name><name><surname>Tur</surname><given-names>JA</given-names></name><name><surname>Pons</surname><given-names>A</given-names></name></person-group><article-title>Lymphocyte antioxidant response and H<sub>2</sub>O<sub>2 </sub>production after a swimming session: gender differences</article-title><source>Free radical research</source><year>2008</year><volume>42</volume><fpage>312</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">18404530</pub-id><pub-id pub-id-type="doi">10.1080/10715760801989926</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vassalle</surname><given-names>C</given-names></name><name><surname>Maffei</surname><given-names>S</given-names></name><name><surname>Boni</surname><given-names>C</given-names></name><name><surname>Zucchelli</surname><given-names>GC</given-names></name></person-group><article-title>Gender-related differences in oxidative stress levels among elderly patients with coronary artery disease</article-title><source>Fertility and sterility</source><year>2008</year><volume>89</volume><fpage>608</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">17548077</pub-id><pub-id pub-id-type="doi">10.1016/j.fertnstert.2007.03.052</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Souza</surname><given-names>CT</given-names></name><name><surname>Araujo</surname><given-names>EP</given-names></name><name><surname>Stoppiglia</surname><given-names>LF</given-names></name><name><surname>Pauli</surname><given-names>JR</given-names></name><name><surname>Ropelle</surname><given-names>E</given-names></name><name><surname>Rocco</surname><given-names>SA</given-names></name><name><surname>Marin</surname><given-names>RM</given-names></name><name><surname>Franchini</surname><given-names>KG</given-names></name><name><surname>Carvalheira</surname><given-names>JB</given-names></name><name><surname>Saad</surname><given-names>MJ</given-names></name><etal></etal></person-group><article-title>Inhibition of UCP2 expression reverses diet-induced diabetes mellitus by effects on both insulin secretion and action</article-title><source>Faseb J</source><year>2007</year><volume>21</volume><fpage>1153</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">17209127</pub-id><pub-id pub-id-type="doi">10.1096/fj.06-7148com</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humphries</surname><given-names>SE</given-names></name><name><surname>Cooper</surname><given-names>JA</given-names></name><name><surname>Talmud</surname><given-names>PJ</given-names></name><name><surname>Miller</surname><given-names>GJ</given-names></name></person-group><article-title>Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men</article-title><source>Clinical chemistry</source><year>2007</year><volume>53</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">17130180</pub-id><pub-id pub-id-type="doi">10.1373/clinchem.2006.074591</pub-id></citation></ref></ref-list></back></article> 